Matthew Posard Biography and Net Worth

Mr. Posard brings over 30 years of general management and commercialization experience in the biotechnology and diagnostics industry to the Board of Directors. He is the Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016. Since 2017, he has provided advisory services to CEOs for several emerging life sciences companies. From February 2017 to April 2018, Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company. From March 2015 to April 2016, he served as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015, he held various commercial and general management positions at Illumina, Inc., a genomics company focusing on DNA sequencing, including senior executive positions overseeing Global Sales, Marketing, and General Manager of Clinical and Consumer Genomics as well as New and Emerging Markets. He currently serves on the Board of Directors of DermTech, Inc, Nautilus Biotechnology, Inc. and Talis Biomedical Corporation. Mr. Posard holds a BA degree in Management Science from the University of California, San Diego. He is the Chair of the Nominating and Corporate Governance Committee.

What is Matthew L. Posard's net worth?

The estimated net worth of Matthew L. Posard is at least $5.52 million as of June 11th, 2024. Mr. Posard owns 109,755 shares of Halozyme Therapeutics stock worth more than $5,517,384 as of June 19th. This net worth approximation does not reflect any other assets that Mr. Posard may own. Learn More about Matthew L. Posard's net worth.

How do I contact Matthew L. Posard?

The corporate mailing address for Mr. Posard and other Halozyme Therapeutics executives is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halozyme Therapeutics can also be reached via phone at 858-794-8889 and via email at [email protected]. Learn More on Matthew L. Posard's contact information.

Has Matthew L. Posard been buying or selling shares of Halozyme Therapeutics?

During the past quarter, Matthew L. Posard has sold $500,100.00 in shares of Halozyme Therapeutics stock. Most recently, Matthew L. Posard sold 10,000 shares of the business's stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $50.01, for a transaction totalling $500,100.00. Following the completion of the sale, the director now directly owns 109,755 shares of the company's stock, valued at $5,488,847.55. Learn More on Matthew L. Posard's trading history.

Who are Halozyme Therapeutics' active insiders?

Halozyme Therapeutics' insider roster includes Jean-Pierre Bizzari (Director), James Daly (Director), Jeffrey Henderson (Director), Kenneth Kelley (Director), Michael LaBarre (SVP), Nicole Labrosse (CFO), Connie Matsui (Director), Matthew Posard (Director), and Helen Torley (CEO). Learn More on Halozyme Therapeutics' active insiders.

Are insiders buying or selling shares of Halozyme Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 180,000 shares worth more than $7,501,100.00. The most recent insider tranaction occured on June, 11th when Director Matthew L Posard sold 10,000 shares worth more than $500,100.00. Insiders at Halozyme Therapeutics own 2.7% of the company. Learn More about insider trades at Halozyme Therapeutics.

Information on this page was last updated on 6/11/2024.

Matthew L. Posard Insider Trading History at Halozyme Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/11/2024Sell10,000$50.01$500,100.00109,755View SEC Filing Icon  
12/5/2022Sell10,000$55.74$557,400.00115,189View SEC Filing Icon  
12/2/2022Sell10,000$58.80$588,000.00125,189View SEC Filing Icon  
See Full Table

Matthew L. Posard Buying and Selling Activity at Halozyme Therapeutics

This chart shows Matthew L Posard's buying and selling at Halozyme Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Halozyme Therapeutics Company Overview

Halozyme Therapeutics logo
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $50.27
Low: $49.00
High: $50.84

50 Day Range

MA: $43.22
Low: $37.81
High: $51.44

2 Week Range

Now: $50.27
Low: $32.83
High: $53.00


1,035,343 shs

Average Volume

1,305,459 shs

Market Capitalization

$6.40 billion

P/E Ratio


Dividend Yield